GENNEX LABORATORIES
|
GENNEX LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 0.50 | 0.35 | 0.32 | 0.32 | 0.15 |
| CEPS(Rs) | 0.68 | 0.33 | 0.36 | 0.37 | 0.22 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 7.24 | 4.53 | 3.46 | 3.14 | 2.82 |
| Tax Rate(%) | 20.11 | 22.79 | 22.98 | 20.23 | 27.16 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 17.32 | 6.53 | 8.24 | 10.26 | 5.42 |
| EBIT Margin(%) | 19.90 | 10.75 | 9.15 | 9.12 | 5.51 |
| Pre Tax Margin(%) | 16.77 | 8.87 | 7.80 | 7.95 | 4.25 |
| PAT Margin (%) | 13.40 | 6.85 | 6.01 | 6.34 | 3.10 |
| Cash Profit Margin (%) | 15.81 | 8.13 | 7.22 | 7.73 | 4.77 |
| Performance Ratios | |||||
| ROA(%) | 7.28 | 4.92 | 6.18 | 6.97 | 3.42 |
| ROE(%) | 10.77 | 7.95 | 9.39 | 10.71 | 5.34 |
| ROCE(%) | 13.64 | 10.19 | 11.82 | 13.24 | 8.36 |
| Asset Turnover(x) | 0.54 | 0.72 | 1.03 | 1.10 | 1.10 |
| Sales/Fixed Asset(x) | 1.17 | 1.17 | 2.14 | 2.10 | 1.99 |
| Working Capital/Sales(x) | 0.81 | 3.75 | 2.84 | 3.67 | 4.25 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.86 | 0.85 | 0.47 | 0.48 | 0.50 |
| Receivable days | 50.53 | 52.65 | 53.05 | 39.96 | 50.76 |
| Inventory Days | 75.85 | 59.51 | 35.67 | 35.71 | 38.85 |
| Payable days | 83.15 | 67.75 | 65.55 | 71.92 | 88.41 |
| Valuation Parameters | |||||
| PER(x) | 31.60 | 16.00 | 22.14 | 11.69 | 12.10 |
| PCE(x) | 23.12 | 16.97 | 20.22 | 10.06 | 8.22 |
| Price/Book(x) | 2.18 | 1.24 | 2.17 | 1.25 | 0.66 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 3.66 | 1.55 | 1.59 | 0.93 | 0.50 |
| EV/Core EBITDA(x) | 14.47 | 11.72 | 14.36 | 7.90 | 6.57 |
| EV/EBIT(x) | 16.22 | 13.12 | 16.26 | 9.60 | 8.36 |
| EV/CE(x) | 1.68 | 1.04 | 1.43 | 0.95 | 0.48 |
| M Cap / Sales | 4.14 | 1.51 | 1.56 | 0.83 | 0.42 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 32.18 | 7.17 | 2.62 | 7.25 | -0.33 |
| Core EBITDA Growth(%) | 153.70 | 27.91 | -4.23 | 68.10 | -12.63 |
| EBIT Growth(%) | 153.25 | 29.41 | 2.85 | 75.81 | -13.58 |
| PAT Growth(%) | 167.74 | 25.43 | -2.85 | 117.53 | -16.41 |
| EPS Growth(%) | 42.57 | 8.06 | 1.67 | 117.59 | -16.43 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.12 | 0.22 | 0.23 | 0.19 | 0.14 |
| Current Ratio(x) | 4.01 | 1.65 | 1.95 | 1.91 | 1.68 |
| Quick Ratio(x) | 3.39 | 1.12 | 1.63 | 1.65 | 1.32 |
| Interest Cover(x) | 6.36 | 5.71 | 6.80 | 7.81 | 4.38 |
| Total Debt/Mcap(x) | 0.05 | 0.17 | 0.11 | 0.15 | 0.21 |
Compare Financial Ratios of peers of GENNEX LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GENNEX LABORATORIES | ₹436.8 Cr | 0.7% | -12.1% | 27.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹431,352.0 Cr | 1.7% | -4.7% | 48.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹159,265.0 Cr | 4.4% | 3.1% | 66% | Stock Analytics | |
| CIPLA | ₹120,035.0 Cr | -0.9% | -1.7% | 17.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,286.0 Cr | -1% | -8.9% | 6.5% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹95,461.4 Cr | -1% | -4% | 48.4% | Stock Analytics | |
GENNEX LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GENNEX LABORATORIES | 0.7% |
-12.1% |
27.6% |
| SENSEX | -1.9% |
-5% |
17.5% |
You may also like the below Video Courses
